Clinical Trials · NCT07505303
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eccogene
- Enrollment
- 151
- Start date
- Mar 2026
- Locations
- 15 sites, United States
- Primary endpoint
- Percentage Change in Body Weight from Baseline (Week 9) to Week 20